TITLE

Options for treating obesity

AUTHOR(S)
Campbell, Ian
PUB. DATE
April 2002
SOURCE
GP: General Practitioner;4/26/2002, p70
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Focuses on the options for general practitioners in treating obesity. Effectiveness of anti-obesity drugs; Requirements for drug administration; Importance of setting realistic targets.
ACCESSION #
6728685

 

Related Articles

  • Long-Term Results of Drug Treatment for Obesity. SLAWSON, DAVID // American Family Physician;3/1/2014, Vol. 89 Issue 5, p389 

    The article presents answers to a question on whether weight loss medications are effective as long-term treatment for obesity.

  • 5 that work. Nachatelo, Melissa // Natural Health;May/Jun2001, Vol. 31 Issue 4, p70 

    Presents information about different natural diet supplements used in the management of obesity. Green tea; Ephedra; Chromium.

  • New experimental drug helps obese patients lose weight.  // New York Amsterdam News;02/25/99, Vol. 90 Issue 9, p14 

    Highlights the results of a study conducted at Baylor College of Medicine in Houston, Texas indicating the potency of orlistat to promote weight loss among obese patients. Need for the combination of moderate-calorie diet; Mechanism of the drug's action; Adverse reactions.

  • Focus On Orlistat: A Nonsystemic Inhibitor Of Gastrointestinal Lipase For Weight Reduction In The Management Of Obesity. Chow, Moses S.S.; Reddy, Prabashni // Formulary;Oct98, Vol. 33 Issue 10, p943 

    Discusses orlistat, a nonsystemic inhibitor of gastrointestinal lipase for weight reduction in the management of obesity. Chemistry and pharmacology; Pharmacokinetics; Clinical trials; Guidelines for obesity therapy; Adverse effects; Drug interaction; Dosage. INSET: Formulary Considerations.

  • Profit in Loss. Wellner, Alison Stein // American Demographics;Jul2000, Vol. 22 Issue 7, p46 

    Discusses the development of the XeniCare program offered to patients using the Roche Laboratories' Xenical prescription obesity drug.

  • GPs should join debate on potential risk versus reward of obesity drug. Castaneda, Reynald // New Zealand Doctor;10/8/2014, p14 

    The article focuses on the debate by general practitioners (GP) and clinicians in New Zealand on the risks and reward of the obesity drug phentermine.

  • A pharmacologic approach to obesity. Lucas, Charles P.; Segal, Karen R.; Hauptman, Jonathan // Contemporary OB/GYN;Jun2000, Vol. 45 Issue 6, p18 

    Evaluates the effectiveness of orlistat for the treatment of obesity. Gender-specific effects of obesity; Effect of orlistat on weight loss; Side effects of orlistat. INSET: Fighting obesity.

  • Obesity market to balloon by 2012, new products set to dominate.  // PharmacoEconomics & Outcomes News;7/17/2004, Issue 457, p11 

    Reports on the possible growth of the market for drugs used in treating obesity according to results of an analysis conducted by Datamonitor. Types of drugs for treating obesity to be introduced in the market.

  • INSIDE AMERICA'S HOTTEST DIET PROGRAMS. Donahue, Peggy Jo // Prevention;Feb90, Vol. 42 Issue 2, p55 

    Looks at Nutri/System, a comprehensive weight-loss and weight-maintenance program. Role in helping people to move from an inactive to an active lifestyle; Two phases of the Nutri/System program; Importance of a high-carbohydrate, low-fat, low-sodium diet regimen; Advantages of the Nutri/System...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics